Is medical dissolution treatment for uric acid stones more cost-effective than surgical treatment? A novel, solo practice, retrospective cost-analysis of medical vs. surgical therapy

Auteurs-es

  • Amihay Nevo University Hospitals Cleveland Medical Center - Urology Institute
  • Mitchell R. Humphreys Mayo Clinic Arizona - Department of Urology
  • Michael Callegari University Hospitals Cleveland Medical Center - Urology Institute
  • Mira Keddis Mayo Clinic Arizona - Department of Nephrology
  • Jonathan P. Moore Mayo Clinic Arizona - Department of Urology
  • Saif Salih Mayo Clinic Arizona - Department of Urology
  • Karen L. Stern Mayo Clinic Arizona - Department of Urology

DOI :

https://doi.org/10.5489/cuaj.7833

Mots-clés :

nephrolithiasis, uric acid, dissolution, cost-effectiveness

Résumé

Introduction: Effective medical dissolution therapy (MDT) for uric acid stones is more cost-effective than surgical treatment; however, treatment failure may be associated with increased cost. We aimed to study the cost-effectiveness of MDT for uric acid stones vs. surgical management.

Methods: We performed a retrospective study within our institution of all patients receiving MDT for uric acid stones from 2008–2019. All patients had a known history of uric acid stones, urine pH ≤5.5, and <500 Hounsfield units on preoperative computed tomography (CT). The cost of treatment in the dissolution group was compared to the cost of primary surgical treatment in a theoretical matched cohort. Cost was estimated using local Medicare reimbursement scales. Statistical analysis was performed with SPSS Statistics.

Results: A total of 28 patients were identified, of which 18 were included in the study. Complete and partial dissolution occurred in six (33%) and four (22%) patients, respectively. Five (28%) patients developed symptoms and underwent ureteral stent placement. Ureteroscopy and percutaneous nephrolithotomy (PCNL) were each performed in three (17%) patients in whom dissolution treatment was not effective on followup CT. Following dissolution trial, six (33%) patients had residual stone burden requiring surgical intervention. The average cost of treatment, including surgeries, was $14 604 in the dissolution group vs. $17 680 in the surgical cohort. The average cost to achieve stone-free status in patients with complete, partial, or no response to dissolution were $1675, $10 124, and $21 584, respectively, while primary surgical treatment for the same patients would cost $15 037, $10 901, and $20 511, respectively.

Conclusions: Successful MDT is highly cost-effective. Incomplete response to dissolution can stem from several reasons and contributes to higher costs and likely decreased quality of life.

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Publié-e

2022-08-30

Comment citer

Nevo, A., Humphreys, M. R., Callegari, M., Keddis, M., Moore, J. P., Salih, S., & Stern, K. L. (2022). Is medical dissolution treatment for uric acid stones more cost-effective than surgical treatment? A novel, solo practice, retrospective cost-analysis of medical vs. surgical therapy. Canadian Urological Association Journal, 17(1), E29–34. https://doi.org/10.5489/cuaj.7833

Numéro

Rubrique

Original Research